CR9410A - Metodos para el tratamiento de abuso y dependencia de sustancias - Google Patents

Metodos para el tratamiento de abuso y dependencia de sustancias

Info

Publication number
CR9410A
CR9410A CR9410A CR9410A CR9410A CR 9410 A CR9410 A CR 9410A CR 9410 A CR9410 A CR 9410A CR 9410 A CR9410 A CR 9410A CR 9410 A CR9410 A CR 9410A
Authority
CR
Costa Rica
Prior art keywords
treatment
methods
abuse
dependence
substances
Prior art date
Application number
CR9410A
Other languages
English (en)
Inventor
Sabnani Sanjay
Wesson Donald
Dunn Joseph
Original Assignee
Hythiam Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hythiam Inc filed Critical Hythiam Inc
Publication of CR9410A publication Critical patent/CR9410A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion es concerniente con metodos de y composiciones para el tratamiento y alivio de sintomas y enfermedad asociados con indicaciones provocadas por un impulso fisiologico a aliviar una sensacion de ansiedad. Mas especificamente, la presente invencion es concerniente con metodos de y composiciones para el tratamiento y alivio de sintomas asociados con abuso y abandono de sustancia.
CR9410A 2005-04-07 2007-10-02 Metodos para el tratamiento de abuso y dependencia de sustancias CR9410A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66903305P 2005-04-07 2005-04-07
US72901305P 2005-10-21 2005-10-21
US72897905P 2005-10-21 2005-10-21

Publications (1)

Publication Number Publication Date
CR9410A true CR9410A (es) 2008-02-21

Family

ID=37087555

Family Applications (2)

Application Number Title Priority Date Filing Date
CR9410A CR9410A (es) 2005-04-07 2007-10-02 Metodos para el tratamiento de abuso y dependencia de sustancias
CR9413A CR9413A (es) 2005-04-07 2007-10-03 Metodos para el tratamiento de alteraciones relacionadas con ansiedad

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR9413A CR9413A (es) 2005-04-07 2007-10-03 Metodos para el tratamiento de alteraciones relacionadas con ansiedad

Country Status (12)

Country Link
US (3) US20080207601A1 (es)
EP (3) EP1868593A2 (es)
JP (3) JP2008538748A (es)
KR (2) KR20080004580A (es)
AU (3) AU2006235318A1 (es)
BR (2) BRPI0610693A2 (es)
CA (3) CA2604887A1 (es)
CR (2) CR9410A (es)
IL (2) IL186447A0 (es)
MX (2) MX2007012355A (es)
NO (2) NO20075155L (es)
WO (3) WO2006110642A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
EP1868593A2 (en) * 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US20090269795A1 (en) * 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
US8586634B2 (en) 2007-06-15 2013-11-19 University Of Florida Research Foundation, Inc. Therapeutic compounds
EP2219612A4 (en) 2007-12-17 2013-10-30 Paladin Labs Inc FORMULATION WITH TAXED RELEASE AND ABUSE PROTECTION
ITRM20080436A1 (it) * 2008-08-06 2010-02-07 Francesco Marrosu Uso della finasteride e di altre sostanze inibenti l'enzima 5-a-reduttasi per la prevenzione e la cura dei disturbi dell'impulso e dell'aggressivita'
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
US8486449B2 (en) 2008-12-16 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
WO2010094074A1 (en) * 2009-02-20 2010-08-26 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
US20120295893A1 (en) * 2009-12-14 2012-11-22 Coeruleus Ltd. Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
AU2011279557B2 (en) * 2010-07-16 2018-09-27 Verita Research Pte Ltd Pharmaceutical compositions for sustained delivery of benzodiazepine antagonists
US8968722B2 (en) * 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) * 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
US20150313915A1 (en) 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
DK2935307T3 (en) * 2012-12-18 2018-07-30 Univ Washington NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
JP6715830B2 (ja) * 2014-06-26 2020-07-01 ザ・ジョンズ・ホプキンス・ユニバーシティ 過敏性腸症候群および末梢神経系の他の病気の治療のための末梢限局性ｇａｂａポジティブアロステリックモジュレーター
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
US20180050005A1 (en) * 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
US10933014B2 (en) * 2017-01-09 2021-03-02 Asarina Pharma Ab Injectable suspension comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, and a method for the manufacturing thereof
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
CA3083850A1 (en) * 2017-03-28 2019-10-04 LDN Pharma Limited An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
KR101898814B1 (ko) 2017-09-07 2018-09-13 백창목 도어 개폐용 도어록
WO2019055942A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING OPIOID TOLERANCE
WO2019055939A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING SYMPTOMS ASSOCIATED WITH OPIOID WEANING
US12414956B2 (en) 2017-09-20 2025-09-16 Calista Capital, Llc Method for smoking cessation
US10966988B2 (en) * 2017-09-20 2021-04-06 Calista Capital, Llc Method for smoking cessation
EP3482751A1 (en) 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
CN111918657A (zh) * 2018-04-05 2020-11-10 阿沙里那制药有限公司 用于治疗物质戒断障碍的gaba-a拮抗剂
EP3761979A4 (en) * 2018-04-06 2021-06-30 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT SUBSTANCE ABUSE
EP3833351A4 (en) 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
US20220152044A1 (en) * 2019-03-14 2022-05-19 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system
AU2020335372B2 (en) 2019-08-26 2025-07-03 Period Pill Bv Treatment of menstrual cycle-induced symptoms
US12233070B2 (en) 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder
CN121695144A (zh) * 2020-11-27 2026-03-20 特雷泽制药私人有限公司 包含氟马西尼和纳曲酮的组合物及其使用方法
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4595684A (en) * 1985-08-16 1986-06-17 Ciba-Geigy Corporation Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
FR2719843B1 (fr) * 1994-05-10 1996-06-07 Synthelabo Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique.
US5521181A (en) * 1995-01-27 1996-05-28 Abbott Laboratories Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists
IT1274481B (it) * 1995-05-12 1997-07-17 Indena Spa Composizioni farmaceutiche per il trattamento della alcol-dipendenza
BR9812144A (pt) * 1997-08-28 2000-07-18 Janus Pharmaceuticals Inc Antagonistas da atividade de androgen como terapias para anorexia, anorexia nervosa e distúrbios caracterizados por uma condiçao de baixo peso patológica
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
WO1999061014A2 (en) 1998-05-28 1999-12-02 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
AU7331300A (en) * 1999-08-27 2001-03-26 Merck & Co., Inc. Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
US20020173495A1 (en) * 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
NZ539400A (en) 2001-01-17 2006-04-28 Hythiam Inc Use of flumazenil in developing a drug for the treatment of alcohol dependence
MXPA03007281A (es) 2001-02-15 2005-01-25 Hythiam Inc Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la dependencia de cocaina.
GB0311859D0 (en) * 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
PT1691811E (pt) * 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence

Also Published As

Publication number Publication date
MX2007012355A (es) 2008-01-16
AU2006235234A1 (en) 2006-10-19
EP1868432A2 (en) 2007-12-26
KR20080004580A (ko) 2008-01-09
US20080207601A1 (en) 2008-08-28
WO2006110557A3 (en) 2009-04-16
EP1901727A4 (en) 2009-11-11
BRPI0610693A2 (pt) 2016-11-22
AU2006235257B2 (en) 2010-11-04
EP1868593A2 (en) 2007-12-26
IL186447A0 (en) 2008-08-07
US20080280885A1 (en) 2008-11-13
NO20075161L (no) 2008-01-07
AU2006235257A1 (en) 2006-10-19
US20080255097A1 (en) 2008-10-16
CR9413A (es) 2008-01-21
WO2006110642A2 (en) 2006-10-19
MX2007012353A (es) 2008-01-16
WO2006110557A2 (en) 2006-10-19
CA2603519A1 (en) 2006-10-19
WO2006110642A3 (en) 2009-04-23
CA2603533A1 (en) 2006-10-19
WO2006110580A2 (en) 2006-10-19
EP1901727A2 (en) 2008-03-26
WO2006110580A3 (en) 2007-08-16
IL186450A0 (en) 2008-01-20
KR20080004581A (ko) 2008-01-09
JP2008535852A (ja) 2008-09-04
CA2604887A1 (en) 2006-10-19
JP2008535850A (ja) 2008-09-04
BRPI0609744A2 (pt) 2010-04-27
EP1868432A4 (en) 2009-11-04
US8012958B2 (en) 2011-09-06
NO20075155L (no) 2008-01-07
JP2008538748A (ja) 2008-11-06
AU2006235318A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
CR9413A (es) Metodos para el tratamiento de alteraciones relacionadas con ansiedad
CR9601A (es) Composiciones y metodos para el tratamiento de sintomas relacionados con el ciclo
GT200600045A (es) Derivados de piridizina y su uso como agentes terapeuticos
ECSP088904A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
CR10347A (es) Anticuerpos contra el peptidob-amiloide
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
UA102065C2 (xx) Заміщені 4-арил-1,4-дигідро-1,6-нафтиридинаміди і їх застосування$замещенные 4-арил-1,4-дигидро-1,6-нафтиридинамиды и их применение
UY30333A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
HRP20070516A2 (en) Methods for treating infectious disease exacerbated asthma
CR11292A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
WO2007142755A3 (en) Purine analogs
EA200802204A1 (ru) Применение ингибиторов dpp iv
UY31484A1 (es) Piperidinas heteroaril-sustituidas
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
CL2007003065A1 (es) Compuestos derivados de benzodioxano, agonista 5ht2c, composicion farmaceutica que lois comprende; y sus uso en el tratamiento de un trastorno psicotico, ansiedad, depresion, trastorno bipolar, sindrome premenstrual, entre otros
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.